“Secukinumab Sustains Individual Clinical Responses Over Time in Patients with Psoriatic Arthritis: 2-Year Results from a Phase 3 Trial”, J of Skin, vol. 2, no. S1, p. S21, Feb. 2018, doi: 10.25251/skin.2.supp.21.